7 février 2025|
AI
|10 months agoBioVersys Makes First Swiss IPO of 2025 with CHF216M Valuation
Basel-based biotech firm BioVersys launches first Swiss IPO of 2025, raising CHF80 million for antibiotic development, with shares starting at CHF36.50 on SIX Swiss Exchange.
AI
Generated IllustrationKey Takeaways
AI
- BioVersys is a Basel-based biotech company focused on treating life-threatening infectious diseases
- The IPO was launched on SIX Swiss Exchange on February 7, 2025
- The company's main product is BV100, targeting hospital infections
By The Numbers
CHF216 million
Market capitalization
CHF80 million
IPO proceeds
CHF36.50
Initial share price
They Said
"Today marks an important milestone for BioVersys as we take the next step in our growth strategy"
"It is a good example of how a biotech company prefers an IPO on SIX Swiss Exchange to an IPO overseas"